Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06206096
Other study ID # ZLNK-CRC-01
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date May 26, 2021
Est. completion date December 2025

Study information

Verified date April 2024
Source Chinese PLA General Hospital
Contact Ru Jia, MD
Phone +8613811721720
Email ashleyjr@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is designed to explore the efficacy and safety of anti-PD-1 antibody plus bevacizumab and chemotherapy as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date December 2025
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Histologically or cytologically confirmed non resectable, locally advanced or metastatic colorectal cancer; - No previous anti-tumor treatment for metastatic diseases; - KRAS/NRAS mutation; - Eastern Cooperation Oncology Group (ECOG) performance status of 0-1; - Life expectancy = 3 months; - Adequate organ and bone marrow functions: Absolute neutrophil count=1.5x10^9/L; Platelet count=100x10^9/L; Hemoglobin=9g/dL; Serum bilirubin<1.5x the upper limit of normal(ULN); Alanine aminotransferase(ALT) and aspartate aminotransferase(AST)<1.5x ULN; Serum creatinine<1.5x ULN; Endogenous creatinine clearance rate = 50ml / min; - Women of childbearing age need to take effective contraceptive measures. Exclusion Criteria: - Previous treatment with vascular endothelial growth factor receptor (VEGFR) inhibitors or previous use of immune checkpoint inhibitors; - With BRAF mutation or MSI-H status; - Other untreated or concurrent tumors (except cervical carcinoma in situ, treated basal cell carcinoma or superficial bladder tumor, or if the tumor is cured and there is no evidence of disease for more than 3 years); - Have received other systemic anti-tumor treatments, including chemotherapy, signal transduction inhibitors, hormone therapy and immunotherapy within 4 weeks before enrollment; - There was central nervous system (CNS) metastasis or previous brain metastasis before enrollment; - Have received any surgery or invasive treatment or operation within 4 weeks before enrollment; - Have received Local anti-tumor therapy such as hepatic artery interventional embolization, liver metastasis cryoablation or radiofrequency ablation within 4 weeks before enrollment; - Uncontrolled malignant ascites; - Participated in other clinical trials within 4 weeks before enrollment, and received corresponding experimental drug treatment; - Allergic to the study drug or any of its adjuvants; - International normalized ratio (INR) > 1.5 or partially activated prothrombin time (APTT) > 1.5 × ULN; - The researchers judged clinically significant electrolyte abnormalities; - Hypertension that cannot be controlled by drugs, which is specified as: systolic blood pressure = 140 mmHg and / or diastolic blood pressure = 90 mmHg; Patients currently have poorly controlled diabetes (fasting glucose level is greater than CTCAE grade 2 after regular treatment); - Patients with dysphagia, active peptic ulcer, intestinal obstruction, active gastrointestinal bleeding, peptic perforation, malabsorption syndrome or uncontrolled intestinal inflammatory diseases; - Any disease or state affecting drug absorption before enrollment, or the patient cannot take oral medication; - Patients with obvious evidence of bleeding tendency or medical history within 3 months before enrollment, hemoptysis or thromboembolism within 12 months; - Cardiovascular diseases with significant clinical significance, including but not limited to acute myocardial infarction, severe / unstable angina pectoris or coronary artery bypass grafting within 6 months before enrollment; Congestive heart failure, New York Heart Association (NYHA) grade > 2; ventricular arrhythmia requiring drug treatment; LVEF (left ventricular ejection fraction) < 50%; - Active infection or serious infection that is not controlled by drug (=CTCAE v5.0 Grade 2); - History of clinically significant hepatic disease, including, but not limited to, known hepatitis B virus (HBV) infection with HBV DNA positive (copies =1×10^4/ml or >2000 IU/ml); known hepatitis C virus infection with HCV RNA positive (copies =1×10^3/m); hepatitis and cirrhosis; - Women who are pregnant or lactating; - Urinary protein = ++, and the 24-hour urine protein quantification is greater than 1.0g; - Have any other disease, metabolic disorder, physical examination anomaly, abnormal laboratory result, or any other conditions that makes the subject not suitable for enrolling according to the judgment of the investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
oxaliplatin+capecitabine+bevacizumab+PD-1 antibody
oxaliplatin will be administered once every 3 weeks at a dose of 130 mg/m2; Capecitabine will be taken orally at a dose of 1g/m2 twice daily for continuous oral administration over 14 days; Bevacizumab will be administered intravenously every 3 weeks at a dose of 7.5 mg/kg; PD-1 antibody was given due to different types.

Locations

Country Name City State
China Chinese PLA General Hospital Beijing

Sponsors (1)

Lead Sponsor Collaborator
Chinese PLA General Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary ORR The proportion of patients with a confirmed complete response or partial response up to 3 years
Secondary PFS The time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first up to 3 years
Secondary OS The time from randomization to death from any reason up to 3 years
Secondary DCR The proportion of patients with a best overall response of confirmed complete or partial response, or stable disease (CR+ PR + SD) up to 3 years
Secondary Safety and tolerability by incidence, severity and outcome of adverse events Safety and tolerance will be evaluated by incidence, severity and outcomes of adverse events (AEs) and categorized by severity in accordance with the NCI CTC AE Version 5.0 up to 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A